FDA News

FDA approves Venclexta-Gazyva regimen for untreated chronic lymphocytic leukemia

May 15, 2019
The FDA approved venetoclax in combination with obinutuzumab for patients with previously untreated chronic lymphocytic leukemia or small lymphocytic…
FDA News

FDA approves Bavencio-Inlyta combination for advanced renal cell carcinoma

May 15, 2019
The FDA approved avelumab in combination with axitinib for first-line treatment of patients with advanced renal cell carcinoma. Avelumab (Bavencio;…
Feature

CAR T cells show potential for treatment of pediatric solid tumors

May 13, 2019
Researchers at Stanford University School of Medicine have used chimeric antigen receptor T cells targeting B7-H3 to attack certain solid tumors in…
FDA News

FDA approves Cyramza for hepatocellular carcinoma

May 11, 2019
The FDA approved ramucirumab as single-agent therapy for certain patients with hepatocellular carcinoma. The approval applies to use of
Feature

Costs, lengths of stay after CAR T-cell therapy greater for younger patients

May 10, 2019
Two studies presented at this year’s Transplantation & Cellular Therapy Meetings provided new insights into treatment costs and hospital…
FDA News

FDA grants fast track designation to leronlimab for metastatic triple-negative breast cancer

May 7, 2019
The FDA granted fast track designation to leronlimab for use in combination with carboplatin for the treatment of patients with CCR5-posiive…
In the Journals

CAR T-cell therapy bb2121 shows promising efficacy, manageable toxicity in multiple myeloma

May 1, 2019
A chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen produced high response rates with manageable toxicity among patients…
Trend Watch

Medicare’s proposed CAR T reimbursement increase ‘woefully inadequate’

April 30, 2019
CMS has announced a proposed 15% increase in the amount it would reimburse hospitals for inpatient CAR T-cell therapy for Medicare patients. The…
In the Journals

Hyperprogressive disease not associated with treatment-related toxicities during immunotherapy

April 26, 2019
Hyperprogressive disease did not appear to be related to clinically significant adverse events, age, tumor type or type of immunotherapy among…
Feature

Trial to assess novel therapeutic approach for kidney cancer

April 25, 2019
Researchers at Dana-Farber Cancer Institute are testing a new treatment strategy designed to improve outcomes for patients with kidney cancer at high…